BEAM THERAPEUTICS INC (BEAM) Stock Price, Quote, News and Overview
NASDAQ:BEAM - Nasdaq - US07373V1052 - Common Stock - Currency: USD
BEAM Quote, Performance and Key Statistics
17
+0.38 (+2.29%)
The current stock price of BEAM is 17 USD. In the past month the price decreased by -25.67%. In the past year, price decreased by -28.87%.
BEAM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About BEAM
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 483 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Company Info
BEAM THERAPEUTICS INC
238 Main Street
Cambridge MASSACHUSETTS 02139 US
CEO: John Evans
Employees: 461
Company Website: https://beamtx.com/
Investor Relations: https://investors.beamtx.com/
Phone: 18573278775
BEAM THERAPEUTICS INC / BEAM FAQ
What is the stock price of BEAM THERAPEUTICS INC today?
The current stock price of BEAM is 17 USD. The price increased by 2.29% in the last trading session.
What is the ticker symbol for BEAM THERAPEUTICS INC stock?
The exchange symbol of BEAM THERAPEUTICS INC is BEAM and it is listed on the Nasdaq exchange.
On which exchange is BEAM stock listed?
BEAM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEAM THERAPEUTICS INC stock?
23 analysts have analysed BEAM and the average price target is 50.49 USD. This implies a price increase of 197% is expected in the next year compared to the current price of 17. Check the BEAM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEAM THERAPEUTICS INC worth?
BEAM THERAPEUTICS INC (BEAM) has a market capitalization of 1.70B USD. This makes BEAM a Small Cap stock.
How many employees does BEAM THERAPEUTICS INC have?
BEAM THERAPEUTICS INC (BEAM) currently has 461 employees.
What are the support and resistance levels for BEAM THERAPEUTICS INC (BEAM) stock?
BEAM THERAPEUTICS INC (BEAM) has a resistance level at 17.01. Check the full technical report for a detailed analysis of BEAM support and resistance levels.
Is BEAM THERAPEUTICS INC (BEAM) expected to grow?
The Revenue of BEAM THERAPEUTICS INC (BEAM) is expected to grow by 16.24% in the next year. Check the estimates tab for more information on the BEAM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEAM THERAPEUTICS INC (BEAM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BEAM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BEAM, evaluating the profitability, health, valuation and growth aspects
- BEAM THERAPEUTICS INC (BEAM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEAM THERAPEUTICS INC (BEAM) Sales and EPS estimates to see what analysts future expectations are.
- BEAM THERAPEUTICS INC (BEAM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEAM THERAPEUTICS INC (BEAM) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEAM THERAPEUTICS INC (BEAM) Stock Chart to make your own analysis
- BEAM THERAPEUTICS INC (BEAM) Latest news and press-releases to stay up to date.
Does BEAM THERAPEUTICS INC (BEAM) stock pay dividends?
BEAM does not pay a dividend.
When does BEAM THERAPEUTICS INC (BEAM) report earnings?
BEAM THERAPEUTICS INC (BEAM) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of BEAM THERAPEUTICS INC (BEAM)?
BEAM THERAPEUTICS INC (BEAM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.58).
What is the Short Interest ratio of BEAM THERAPEUTICS INC (BEAM) stock?
The outstanding short interest for BEAM THERAPEUTICS INC (BEAM) is 12.13% of its float. Check the ownership tab for more information on the BEAM short interest.
BEAM Technical Analysis
BEAM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BEAM. The financial health of BEAM is average, but there are quite some concerns on its profitability.
BEAM Financial Highlights
Over the last trailing twelve months BEAM reported a non-GAAP Earnings per Share(EPS) of -4.58. The EPS decreased by -141.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.13% | ||
| ROE | -51.36% | ||
| Debt/Equity | 0 |
BEAM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BEAM. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of -6.98% and a revenue growth 16.24% for BEAM